Skip to content
value.today

Epicrispr Biotechnologies, Inc.

Total raised
$177 M
1 round on record
Latest round
$177 M
May 2018
First round on record
May 2018
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Epicrispr Biotechnologies, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2018$177 MNo. 1$50 to $250 million

Epicrispr Biotechnologies, Inc.: Raise no. 1, May 2018

Investors in this round

47 investors had bought by the notice of Aug 26, 2026: 47 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$177 M of $213 M offered; $36 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Amber Salzman · Executive Officer, Director
  • Haorui Zhang · Executive Officer, Director
  • Andrew Lam · Director
  • Anran Li · Director
  • Eric Crombez · Director
  • Jennifer King · Director
  • Lei Qi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Series Seed Preferred: $2,499,999.60; Series A-1 Preferred: $51,449,986.60; Series B Preferred: $58,055,021.19; Series B warrants: $1,225.78; Series B-1 Preferred: $10,750,000; Series C Preferred: $53,999,398.66; Series C warrants: $35,999,598.70.”

Signed by Amber Salzman, Chief Executive Officer. Newest notice filed Aug 26, 2026. Read the notice at the SEC.

equity, optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Epicrispr Biotechnologies, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2026).

    SEC Form D · Aug 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2026

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Epicrispr Biotechnologies, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Epicrispr Biotechnologies, Inc.
NameRoleNamed in
Amber SalzmanExecutive officerAug 2026
Haorui ZhangExecutive officerAug 2026
Amber SalzmanDirectorAug 2026
Andrew LamDirectorAug 2026
Anran LiDirectorAug 2026
Eric CrombezDirectorAug 2026
Haorui ZhangDirectorAug 2026
Jennifer KingDirectorAug 2026
Lei QiDirectorAug 2026